Millipore Sigma Vibrant Logo

100050 1400W - CAS 214358-33-5 - Calbiochem

A selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM).

1400W - CAS 214358-33-5 - Calbiochem: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: N-(3-Aminomethyl)benzylacetamidine, 2HCl

Primary Target: iNOS
View Products on Sigmaaldrich.com
100050
Ver precios y disponibilidad

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
214358-33-5C₁₀H₁₅N₃ · 2HCl

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
100050-5MG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 5 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewA selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM). Suitable for use in both in vitro and in vivo systems. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
      Catalogue Number100050
      Brand Family Calbiochem®
      SynonymsN-(3-Aminomethyl)benzylacetamidine, 2HCl
      References
      ReferencesParmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
      Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
      Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
      Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
      Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
      Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
      Product Information
      CAS number214358-33-5
      ATP CompetitiveN
      FormWhite solid
      Hill FormulaC₁₀H₁₅N₃ · 2HCl
      Chemical formulaC₁₀H₁₅N₃ · 2HCl
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetiNOS
      Primary Target IC<sub>50</sub>Kd = 7 nM against inducible nitric oxide synthase (iNOS)
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      100050-5MG 04055977226867

      Documentation

      1400W - CAS 214358-33-5 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      1400W - CAS 214358-33-5 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      100050

      Referencias bibliográficas

      Visión general referencias
      Parmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
      Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
      Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
      Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
      Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
      Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.

      Folleto

      Cargo
      Pathways and Biomarkers of Oxidative Stress

      Citas

      Título
    • Peyssonnaux, C., et al. 2005. The Journal of Clinical Investigation 115, 1860.
      		•
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-April-2011 RFH
      SynonymsN-(3-Aminomethyl)benzylacetamidine, 2HCl
      DescriptionA selective, irreversible, slow, tight binding inhibitor of inducible nitric oxide synthase (iNOS, Kd = 7 nM) both in vitro and in vivo. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number214358-33-5
      Chemical formulaC₁₀H₁₅N₃ · 2HCl
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityMethanol (5 mg/ml) or H₂O (1 mg/ml)
      Storage -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesParmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
      Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
      Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
      Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
      Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
      Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
      Citation
    • Peyssonnaux, C., et al. 2005. The Journal of Clinical Investigation 115, 1860.
      		•